Details of the Drug

General Information of Drug (ID: DMK9IPF)

Drug Name

JNJ-73841937

Synonyms

Lazertinib; 1903008-80-9; GNS-1480; YH25448; YH-25448; UNII-4A2Y23XK11; GNS1480; 4A2Y23XK11; N-(5-((4-(4-((Dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamide; N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenylpyrazol-1-yl]pyrimidin-2-yl]amino]-4-methoxy-2-morpholin-4-ylphenyl]prop-2-enamide; N-{5-[(4-{4-[(dimethylamino)methyl]-3-phenyl-1H-pyrazol-1-yl}pyrimidin-2-yl)amino]-4-methoxy-2-(morpholin-4-yl)phenyl}prop-2-enamide; Lazertinib [USAN]; Lazertinib [INN]; Lazertinib (YH25448,GNS-1480); CHEMBL4558324; SCHEMBL17670400; GTPL10136; BCP30440; EX-A1912; JNJ-73841937-AAA; s8724; WHO 10587; CCG-270023; YH-25448;GNS-1480; BS-15742; Compound 73 [WO2016060443A2]; HY-109061; AK00779508; CS-0032992; A16827; C-18112003-G; YH-25448; YH 25448; YH25448; GNS-1480; GNS 1480; GNS1480; 2-Propenamide, N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)-; CN(C)CC=1C(=NN(C=1)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N1CCOCC1)OC)C1=CC=CC=C1; N-(5-((4-(4-((Dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)acrylamide; N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25.Y	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C30H34N8O3
Canonical SMILES: CN(C)CC1=CN(N=C1C2=CC=CC=C2)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N5CCOCC5)OC
InChI: 1S/C30H34N8O3/c1-5-28(39)32-23-17-24(26(40-4)18-25(23)37-13-15-41-16-14-37)33-30-31-12-11-27(34-30)38-20-22(19-36(2)3)29(35-38)21-9-7-6-8-10-21/h5-12,17-18,20H,1,13-16,19H2,2-4H3,(H,32,39)(H,31,33,34)
InChIKey: RRMJMHOQSALEJJ-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 121269225
CAS Number: 1903008-80-9
TTD ID: DR3FA8

References

1	ClinicalTrials.gov (NCT04077463) A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer. U.S. National Institutes of Health.